Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

P. E. Bendheim, B. Poeggeler, E. Neria, V. Ziv, Miguel Pappolla, D. G. Chain

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)213-217
Number of pages5
JournalJournal of Molecular Neuroscience
Volume19
Issue number1-2
StatePublished - Aug 2002
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Neuroprotective Agents
Oxidants
Reactive Oxygen Species
Oxidative Stress
Oxidative stress
propionic acid
indole
Therapeutics

Keywords

  • Alzheimer's disease
  • Beta-amyloid
  • Indole-3-propionic acid
  • Oxidative stress

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry
  • Genetics

Cite this

Bendheim, P. E., Poeggeler, B., Neria, E., Ziv, V., Pappolla, M., & Chain, D. G. (2002). Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease. Journal of Molecular Neuroscience, 19(1-2), 213-217.

Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease. / Bendheim, P. E.; Poeggeler, B.; Neria, E.; Ziv, V.; Pappolla, Miguel; Chain, D. G.

In: Journal of Molecular Neuroscience, Vol. 19, No. 1-2, 08.2002, p. 213-217.

Research output: Contribution to journalArticle

Bendheim, PE, Poeggeler, B, Neria, E, Ziv, V, Pappolla, M & Chain, DG 2002, 'Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease', Journal of Molecular Neuroscience, vol. 19, no. 1-2, pp. 213-217.
Bendheim PE, Poeggeler B, Neria E, Ziv V, Pappolla M, Chain DG. Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease. Journal of Molecular Neuroscience. 2002 Aug;19(1-2):213-217.
Bendheim, P. E. ; Poeggeler, B. ; Neria, E. ; Ziv, V. ; Pappolla, Miguel ; Chain, D. G. / Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease. In: Journal of Molecular Neuroscience. 2002 ; Vol. 19, No. 1-2. pp. 213-217.
@article{b608d121b18245be8a02286fc887c10d,
title = "Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease",
abstract = "The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.",
keywords = "Alzheimer's disease, Beta-amyloid, Indole-3-propionic acid, Oxidative stress",
author = "Bendheim, {P. E.} and B. Poeggeler and E. Neria and V. Ziv and Miguel Pappolla and Chain, {D. G.}",
year = "2002",
month = "8",
language = "English (US)",
volume = "19",
pages = "213--217",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "1-2",

}

TY - JOUR

T1 - Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

AU - Bendheim, P. E.

AU - Poeggeler, B.

AU - Neria, E.

AU - Ziv, V.

AU - Pappolla, Miguel

AU - Chain, D. G.

PY - 2002/8

Y1 - 2002/8

N2 - The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

AB - The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Indole-3-propionic acid

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=0036675722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036675722&partnerID=8YFLogxK

M3 - Article

C2 - 12212784

AN - SCOPUS:0036675722

VL - 19

SP - 213

EP - 217

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 1-2

ER -